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vaccine.] Pesquisa Veterinária Brasileira 25(1):54-58. Instituto de Pesquisa Veterinária Desidério
Finamor, Fepagro-Saúde Animal, Cx. Postal 47, Eldorado do Sul, RS 92990-000, Brazil. E-mail:
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 Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of respiratory, reproductive
disease and abortion in cattle. Vaccination is widely applied to minimize losses induced by BoHV-1
infections; however, vaccination of dams during pregnancy with modified live virus (MLV) vaccines
has been occasionally associated to abortions. We have previously reported the development of a
BoHV-1 recombinant virus, constructed with basis on a Brazilian BoHV-1 (Franco et al. 2002a) from
which the gene coding for glycoprotein E (gE) was deleted (gE-) by genetic manipulation. Such
recombinant has been previously evaluated in its potential as a differential vaccine (gE- vaccine)
that allows differentiation between vaccinated and infected animals. Here, in the first part of the
present study, the safety of the gE- vaccine during pregnancy was evaluated by the intramuscular
inoculation of 107.4 tissue culture 50 % infective doses (TCID50) of the virus into 22 pregnant dams
(14 BoHV-1 seronegative; 8 seropositive), at different stages of gestation. Other 15 pregnant dams
were kept as non-vaccinated controls. No abortions, stillbirths or fetal abnormalities were seen
after vaccination. Seroconversion was observed in both groups of previously seronegative
vaccinated animals. In the second part of the study, the potential of the gE- vaccine virus to spread
among beef cattle under field conditions was examined. Four heifers were inoculated intranasally
with a larger amount (107,6 TCID50) of the gE- vaccine (to increase chances of transmission) and
mixed with other sixteen animals at the same age and body condition, in the same grazing area, at
a population density equal to the average cattle farming density within the region (one cattle head
per 10,000 m2), for 180 days. All animals were monitored daily for clinical signs. Serum samples
were collected on days 0, 30, 60 and 180 post-vaccination. Seroconversion was observed only in
vaccinated heifers. These results indicate that, under the conditions of the present study, the gE-
vaccine virus did not cause any noticeable harmful effect on pregnant dams and on its offspring
and did not spread horizontally among cattle.
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serological test capable of recognizing antibodies to the deleted
protein is available (Belknap et al. 1999, Flores et al. 1993, Fran-
co et al. 2002a). Such vaccines are often referred to as “differential
vaccines” (Wentink et al. 1993). Recently, we constructed a
glycoprotein E (gE)-negative BoHV-1 recombinant, based on an
autochthonous Brazilian strain of BoHV-1. Such recombinant is
intended for use as an attenuated, differential vaccine (Franco et
al. 2002b) and, as such, was shown to be safe and efficacious for
calves (Franco et al. 2002a), yet allowing differentiation between
vaccinated and infected animals. An important drawback
occasionally found on other MLV is that those may also lead to
embryonic, fetal death and abortions (Miller et al. 1989, McFelly
et al. 1968, Mitchell 1974, Whetstone et al. 1986). Therefore, it is
essential to investigate whether any new vaccine candidate would
bring undesirable side effects if eventually administered during
gestation. Another important issue on MLVs is its potential to
spread within the herd (Pastoret et al. 1980). This is an undesirable
side effect, since the vaccine virus may perpetuate within herds
(Hage et al. 1996). Therefore, it would be of interest to examine
whether the differential vaccine virus might spread within a herd.
In the present study, it was initially aimed to determine the
safety of the gE- vaccine for pregnant dams. Subsequently, the
potential of the gE- vaccine to spread within a herd under typical
beef cattle field conditions was examined.
MATERIALS AND METHODS
Multiplication of the gE- vaccine virus
The construction of the recombinant vaccine virus (265gE-), which
gave rise to the gE-negative vaccine (gE- vaccine), was described
previously (Franco et al. 2002a). The virus was multiplied in CRIB-1
cells (Flores & Donis 1995). BoHV-1 strain EVI 123/98, a typical
representative of BoHV-1.1 isolated in Brasil (D’Arce et al. 2002), was
multiplied in CRIB-1 cells and used for serum neutralization (SN)
assays. Cell cultures were maintained in Eagle’s minimal essential
medium (EMEM) supplemented with 5 % to 10 % fetal bovine serum
(FBS; Nutricell), 2 mM glutamine and antibiotics (100 IU/ml penicillin
and 100 mg/ml streptomycin) following standard procedures.
Safety for pregnant dams
Dams and immunization. Thirty seven pregnant dams of
mixed European beef breeds were used in the experiment. Twenty
two, 2 to 4 years-old dams, were vaccinated intramuscularly (IM) on
the side of the neck with 3 mL of a suspension containing 107.4 TCID50
of the gE- vaccine virus in EMEM. Fourteen pregnant dams in different
stages of gestation were seronegative for BoHV-1 at the start of the
experiment. Another group consisted of eight BoHV-1-seropositive
pregnant dams an additional group of 15 pregnant dams were kept as
non-vaccinated controls. From the control group, at the start of the
experiment, seven dams were BoHV-1 seronegative and 8 were
seropositive for BoHV-1. The stage of pregnancy was determined by
rectal palpation and confirmed by the date of parturition. Table 1
shows the stages of pregnancy of dams within different groups.
Vaccine virus spread in a seronegative herd
 Animals and vaccine virus inoculation. Twenty Aberdeen
Angus heifers, aged 18 months, all seronegative for BoHV-1, were
selected from the stock of the institution of origin of the authors.
Four heifers were inoculated by nasal instillation (IN) of 3 mL of a viral
suspension containing 107.6 TCID50 of the gE- vaccine virus. The animals
RESUMO.- [Avaliação a campo da segurança para vacas
prenhes e capacidade de disseminação horizontal de
uma vacina diferencial recombinante contra o Herpes-
vírus Bovino tipo 1 (BoHV-1).] Infecções pelo herpesvírus
bovino tipo 1 (BoHV-1) são importantes causas de doença respira-
tória, reprodutiva e abortos em bovinos. A vacinação é
freqüentemente empregada para minimizar as perdas produzi-
das pela infecção. Todavia, a imunização de vacas durante a pre-
nhez com algumas vacinas contendo vírus vivo modificado (MLV)
pode ocasionalmente causar abortos. Em trabalho prévio, nosso
grupo desenvolveu uma vacina recombinante de BoHV-1
construída a partir de um isolado brasileiro de BoHV-1 (Franco et
al., 2002a) do qual o gene que codifica para a glicoproteína E (gE)
foi artificialmente deletado. Tal recombinante (gE-) vem sendo
avaliado como vacina diferencial, isto é, capaz de permitir a dife-
renciação entre animais vacinados e infectados. No presente estu-
do, o potencial de disseminação do vírus recombinante foi avalia-
do em um rebanho de gado de corte, em condições de campo.
Para tanto, a segurança da vacina gE- quando aplicada durante a
prenhez foi avaliada pela inoculação intramuscular de 107,4 doses
infectantes para 50% dos cultivos celulares (DICC50) do vírus em
22 fêmeas prenhes (14 previamente soronegativas e 8 previamen-
te soropositivas para BoHV-1) em diferentes fases da gestação.
Outras 15 vacas prenhes foram mantidas como controles não-
vacinados. Não ocorreram abortos, natimortos ou anormalidades
fetais em nenhum dos grupos. Soroconversão foi observada nas
fêmeas vacinadas previamente soronegativas. Em um segundo
experimento, 4 novilhas foram inoculadas pela via intranasal com
107,6 DICC50 do vírus recombinante, sendo mantidos em contato
com 16 novilhas em uma área de campo, a uma densidade de 1
animal por hectare. Os animais foram monitorados quanto à pre-
sença de sinais clínicos; amostras de soro foram coletadas nos
dias 0, 30, 60 e 180 após a vacinação. Soroconversão foi observa-
da apenas nos animais vacinados e não nos contatos. Estes resul-
tados indicam que, nas condições do presente estudo, a vacina
gE- não tem efeitos deletérios para fêmeas gestantes nem para
seus fetos e não se dissemina horizontalmente no rebanho.
TERMOS DE INDEXAÇÃO: Herpesvírus bovino tipo 1, vacina
recombinante gE- contra BoHV-1.
INTRODUCTION
Bovine herpesvirus type 1 (BoHV-1) has been associated with a
number of different clinical manifestations in cattle, such as
infectious bovine rhinotracheitis (IBR) and infectious pustular
vulvovaginitis/ infectious pustular balanoposthitis (IPV/ IPB). The
most striking effect of BoHV-1 infection is its capacity to interfe-
re in gestation, often leading to termination of pregnancy, with
serious economical consequences (Guy & Potgieter, 1985; Miller
et al. 1991, Siebert et al. 1995a, Turin et al. 1999). To minimize
such losses, both conventional modified live or inactivated as
well as recombinant vaccines have been widely used (Kleiboeker
et al. 2003, Turin et al. 1999).
One of the recent strategies for the development of BoHV-1
vaccines relies on the deletion of non-essential genes from the
viral genome. Such deletions allow the distinction between wild
type virus-infected and vaccinated animals, provided that a
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were observed daily for clinical signs. Serum samples were collected
on days 0, 30, 60 and 180 days post-vaccination (DPV).
Seroneutralization assays (SN) were performed as described below.
Any seronconversion to BoHV-1 during this period was assumed as
induced by the vaccine virus. The animals were kept under field
conditions throughout the experiment, in a grazing area of 10.000
m2, at a density of 1 animal per 10.000 m2 for six months. Serum
samples were collected from the dams by caudal or jugular
venipuncture on days 0, 40 and 80 post-vaccination (PV). Samples
were also taken from the calves born from the dams under study,
during the first 2 weeks of life. Sera were tested in serial twofold
dilutions in a standard BoHV-1 neutralizing antibody test against
strain EVI 123/ 98 (Franco et al. 2002).
Statistical analysis
The results were statistically evaluated by analysis of variance
(ANOVA); the least significance difference for p = 0.05 was determined.
Statistical analysis was performed with Data Analysis Supplement
for Exceltm (Office XP for Windowstm, Microsoft Corp., USA). The term
“significant” (statistically significant) in the text means p= 0.05.
RESULTS
Safety for pregnant dams
No embryonic deaths, abortions and stillbirths were detected
in any vaccinated dam throughout the experiment. Likewise, no
reproductive abnormalities were detected on the group of non-
vaccinated dams. Seroconversion was observed in vaccinated
dams that were seronegative at the start of the experiment, as
demonstrated by SN (Fig.1). On the other hand, previously
seropositive dams had no significant alterations in their serum
neutralizing antibody titres (Fig.1).
Vaccine virus spread in a seronegative herd
All four animals vaccinated IN developed a strong immune
response against BoHV-1, as measured by SN assays. Only mild
clinical signs, characterized by light serous discharges from days
1 to 7 PV, were observed on vaccinated heifers. In contrast, no
seroconversion was detected on “in contact” cattle. These results
demonstrate that the vaccine virus was not capable of spreading
from vaccinated to contact animals.
DISCUSSION
Although vaccination with MLV for IBR virus is recognized as an
efficient way to improve herd immunity to BoHV-1 infections
(Wentik et al. 1993, Siebert et al. 1995a), the use of this kind of
vaccines during pregnancy may result in fertility problems such
as early embryonic deaths, abortions and stillbirths (Lomba et al.
1976, Whetstone et al. 1986).
In order to examine the effect of the gE- vaccine during
pregnancy, in the first experiment of the present study
seronegative and seropositive dams were vaccinated
intramuscularly with a gE- vaccine. Vaccination was performed
via IM in order to increase the chances of the virus reaching the
conceptuses. Despite the inoculation of a large dose of vaccine
virus (107.4 TCID50) no detectable harmful effect was observed,
neither on pregnant dams nor on its offspring, demonstrating
its safety for application during pregnancy, at least under the
conditions of the present study. Another gE- vaccine (Siebert et
al. 1995b) had been also evaluated on pregnant cattle, with simi-
lar results. However, other recombinants with a functional gE
gene retained its abortigenic capacity (Miller et al. 1995). Such
studies, when examined  comparatively with the one here
reported, suggest that there may be a link between the apparent
lack of ability to reach and/or cause fetal damage might be
specifically linked to the removal of the gE gene. Further studies
should be able to determine whether gE in fact plays a significant
role leading to abnormalities during gestation.
In addition to being apparently safe for pregnant dams, the
gE- vaccine was capable of inducing high levels of neutralizing
antibodies on vaccinated dams. This is beneficial for the passive
transfer of antibodies to the newborn, as shown for other
herpesviruses (Casal et al. 2004) and also in response to other
viruses (Roehe 1991). In fact, some of the calves born to vaccinated
dams in the present study had higher levels of neutralizing
antibodies than their own dams. Others have speculated that higher
antibody titres in newborns were associated to intrauterine
infection with the vaccine virus (Lomba et al. 1976). In our view, a
more likely possibility is that a physiological concentration of
immunoglobulins in the colostrum would allow more effective
Fig.1. Neutralizing antibody titres (geometric mean) in dams vaccinated
(or not) with the bovine herpesvirus type 1 (BoHV-1) gE-negative
vaccine. Black losenges: vaccinated, previously seropositive animals;
White triangles: non-vaccinated, previously seropositive animals;
Black squares: vaccinated, previously seronegative animals; Blank
circles: non-vaccinated, seronegative animals.
Table 1. Serological status to bovine herpesvirus type 1
(BoHV-1) and approximate stage of pregnancy of dams
vaccinated (or not) with the recombinant gE-negative
vaccine
Group Serological 1st trimester 2nd trimester 3rd trimester
at day 0
status
Vaccinated Seronegative 4a 5 5
Seropositive 3 2 3
Non-vaccinated Seronegative 1 3 3
Seropositive 2 2 4
a Number of pregnant dams in that stage of gestation.
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transfer of these to the newborn, as also pointed out by others
(Odde 1988, Roehe 1991, Ellis et al. 1996).
Interestingly, vaccination of previously seropositive dams led
to no significant rise in antibody levels after immunization. In fact,
neutralizing antibody levels in such animals showed a tendency to
decline at 80 DPV. As neutralizing antibody levels in such dams
were already relatively high, it is possible that the vaccine virus
could have been inactivated by the host’s defense mechanisms,
such as shown for pseudorabies virus (PrV) in swine (Zuckermann
et al. 1998).
The route of inoculation might also play a role in nasal virus
spread. In the experiment designed to detect nasal virus spread,
the inoculation was performed via IN and with a larger amount
of virus, since this could increase the possibility of shedding.
Transmission following IM inoculation is much less likely to occur
(Siebert et al. 1995b, Mars et al. 2000). Despite IN inoculation, no
transmission of the vaccine virus to herdmates was detected.
The sixteen “in contact” animals kept as sentinels did not
seroconvert to BoHV-1 up to six months after vaccination. This
was probably a result of the poor replication of the gE- virus in
the host. Viral spread within a herd is not dependent on the herd
size, but is directly related to the agent’s ability to replicate
efficiently in the host and be shed to contacts (Bouma et al.
1995, Hage et al. 1996). We have previously demonstrated (Fran-
co et al. 2002a), that the gE- virus evaluated here replicates to
very low titres in calves, as has also been shown for another gE-
strain (Kaashoek, 1995, Strube et al. 1995, Mars et al. 2000).
Such poor replication does not favor efficient transmission, as
apparent in the experiment here described. Therefore, at the
cattle density employed here, it seems that the gE- vaccine would
not spread within the herd.
The experiments reported here suggest that the gE- vaccine
was not hazardous to dams vaccinated during gestation. In
addition, it did not spread horizontally to herdmates under usu-
al beef cattle farming conditions usually employed for this region.
These studies will be extended in the future to evaluate the efficacy
of the gE-deleted vaccine in preventing abortions following
challenge of pregnant dams with wild type BoHV-1.
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